# Severe Asthma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/severe-asthma

> 10 upcoming FDA catalysts in severe Asthma: Symbicort Aerosphere (budesonide; formoterol fumarate, AZN) on Jun to Sep 2027 (topline data readout); Symbicort Aerosphere (budesonide; formoterol fumarate, AZN) on June 2027 (primary completion); verekitug (UPB) on September 2027 (primary completion); verekitug (UPB) on Sep to Dec 2027 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 16, 2025 | [Verekitug (upb-101) primary completion](https://sec-api.dev/pdufa/verekitug-upb-101) | UPB | Severe Asthma | completed | "NCT06196879 (A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Upstream Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06196879)) |
| Jun to Sep 2027 | [Symbicort Aerosphere (budesonide; formoterol fumarate) topline data readout](https://sec-api.dev/pdufa/budesonide-formoterol) | AZN | Severe Asthma | scheduled | "NCT06473779 (Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06473779)) |
| June 2027 | [Symbicort Aerosphere (budesonide; formoterol fumarate) primary completion](https://sec-api.dev/pdufa/budesonide-formoterol) | AZN | Severe Asthma | scheduled | "NCT06473779 (Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06473779)) |
| September 2027 | [Verekitug primary completion](https://sec-api.dev/pdufa/verekitug) | UPB | Severe Asthma | scheduled | "NCT06966479 (A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Upstream Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06966479)) |
| Sep to Dec 2027 | [Verekitug topline data readout](https://sec-api.dev/pdufa/verekitug) | UPB | Severe Asthma | scheduled | "NCT06966479 (A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Upstream Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06966479)) |
| Feb to May 2028 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Severe Asthma | scheduled | "NCT07363642 (Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363642)) |
| February 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Severe Asthma | scheduled | "NCT07363642 (Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-07 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363642)) |
| December 2028 | [GB-0895 primary completion](https://sec-api.dev/pdufa/gb-0895) | GENB | Severe Asthma | scheduled | "NCT07276724 (A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Generate Biomedicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276724)) |
| Dec 2028 to Mar 2029 | [GB-0895 topline data readout](https://sec-api.dev/pdufa/gb-0895) | GENB | Severe Asthma | scheduled | "NCT07276724 (A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Generate Biomedicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276724)) |
| January 2029 | [GB-0895 primary completion](https://sec-api.dev/pdufa/gb-0895) | GENB | Severe Asthma | scheduled | "NCT07359846 (A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Generate Biomedicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07359846)) |
| Jan to Apr 2029 | [GB-0895 topline data readout](https://sec-api.dev/pdufa/gb-0895) | GENB | Severe Asthma | scheduled | "NCT07359846 (A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Generate Biomedicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07359846)) |

## Drugs

- [Verekitug (upb-101)](https://sec-api.dev/pdufa/verekitug-upb-101) (UPB)
- [Symbicort Aerosphere (budesonide; formoterol fumarate)](https://sec-api.dev/pdufa/budesonide-formoterol) (AZN)
- [Verekitug](https://sec-api.dev/pdufa/verekitug) (UPB)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [GB-0895](https://sec-api.dev/pdufa/gb-0895) (GENB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/severe-asthma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Severe Asthma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/severe-asthma

```bibtex
@misc{secapidev_indications_severe_asthma_20261116,
  title        = {Severe Asthma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/severe-asthma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_severe_asthma_20261116","title":"Severe Asthma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/severe-asthma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
